INCB050465
Drug timelines are a Plus or Pro feature.
10 regulatory and trial events tracked for INCB050465, covering 2020-04-24 to 2025-08-21. Get the full timeline:
Most recent: Clinical Trial Update: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) [Phase 1]